Business Context and Reporting Period
Inmune Bio, Inc. (INMB), an emerging growth company incorporated in Nevada, filed this Form 8-K on March 22, 2022. The report details a private placement transaction involving the sale of unregistered equity securities to accredited investors, including key executives and board members.
Key Financial Metrics
This filing reports on a specific capital raise event rather than periodic financial performance. Key metrics from the transaction include:
- Gross Proceeds: $698,847
- Shares Issued: 82,900 shares of common stock
- Price Per Share: $8.43 (based on the closing price on March 22, 2021)
- Revenue, Profit, Cash Flow, Debt, and Liquidity: The filing text does not provide a clear value for these general financial metrics; it focuses solely on the proceeds from this specific offering.
Material Changes
The primary material change is the increase in outstanding common stock by 82,900 shares and the infusion of approximately $699,000 in cash. The transaction was executed under a Securities Purchase Agreement and relied on exemptions from registration under Section 4(a)(2) and Rule 506(b) of Regulation D.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the securities were unregistered and sold for investment purposes only. The transaction involved significant participation from company insiders:
- Dr. Raymond J. Tesi (CEO): Purchased 23,724 shares
- David Moss (CFO): Purchased 17,793 shares
- Mark Lowdell (CSO): Purchased 23,590 shares
- J. Kelly Ganjei (Director): Purchased 17,793 shares
Investor Verification Checklist
- Verify the total number of outstanding shares post-transaction to assess dilution impact.
- Confirm the use of proceeds in subsequent filings or press releases.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for any restrictive covenants or rights attached to the shares.
- Check for any related party transaction disclosures regarding the insider purchases.